Sarepta Therapeutics’ (SRPT) “Buy” Rating Reaffirmed at Mizuho

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating)‘s stock had its “buy” rating reiterated by Mizuho in a research note issued on Friday, Benzinga reports. They presently have a $160.00 price objective on the biotechnology company’s stock. Mizuho’s target price would indicate a potential upside of 30.41% from the company’s previous close.

SRPT has been the topic of several other research reports. BTIG Research upped their price target on Sarepta Therapeutics from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, December 22nd. Robert W. Baird increased their target price on Sarepta Therapeutics from $152.00 to $202.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 1st. Needham & Company LLC cut their price target on Sarepta Therapeutics from $200.00 to $160.00 and set a “buy” rating on the stock in a report on Friday. Credit Suisse Group dropped their price objective on Sarepta Therapeutics from $144.00 to $139.00 and set a “neutral” rating on the stock in a report on Friday. Finally, UBS Group upgraded Sarepta Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $100.00 to $158.00 in a research note on Friday, December 16th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $165.88.

Sarepta Therapeutics Stock Down 18.0 %

Shares of SRPT opened at $122.69 on Friday. The company has a current ratio of 4.13, a quick ratio of 3.80 and a debt-to-equity ratio of 4.01. Sarepta Therapeutics has a one year low of $61.28 and a one year high of $159.84. The stock has a 50 day moving average price of $129.49 and a 200 day moving average price of $120.17.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last issued its earnings results on Tuesday, February 28th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.28) by $0.04. The company had revenue of $258.43 million during the quarter, compared to analysts’ expectations of $250.51 million. Sarepta Therapeutics had a negative return on equity of 117.29% and a negative net margin of 75.40%. The firm’s quarterly revenue was up 28.3% on a year-over-year basis. During the same period in the prior year, the business earned ($1.42) EPS. As a group, analysts forecast that Sarepta Therapeutics will post -4.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds have recently bought and sold shares of the stock. FourThought Financial LLC increased its position in Sarepta Therapeutics by 43.5% during the third quarter. FourThought Financial LLC now owns 297 shares of the biotechnology company’s stock worth $33,000 after buying an additional 90 shares in the last quarter. Hanseatic Management Services Inc. purchased a new stake in shares of Sarepta Therapeutics in the third quarter valued at $35,000. Armstrong Advisory Group Inc. purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at $39,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Sarepta Therapeutics in the third quarter valued at $44,000. Finally, C M Bidwell & Associates Ltd. grew its position in shares of Sarepta Therapeutics by 1,966.7% in the second quarter. C M Bidwell & Associates Ltd. now owns 620 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 590 shares during the period. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.